A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy
Phase: PHASE1
Conditions: Advanced Prostate Cancer
Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

ClinicalTrials.gov Cover Page 
Document: Clinical Protocol 
Oﬃcial Study Title: 
A Phase 1/2a Open-label, Mul:center, Dose Escala:on and Dose 
Expansion Study of the Safety, Tolerability, and Pharmacokine:cs of 
HPN424 in Pa:ents with Advanced Prostate Cancer Refractory to 
Androgen Therapy 
Document Date: 24 September 2021 
NCT03577028